Increase access to trials, particularly (but not solely) immunotherapy trials, for previous clinical trial participants, thereby increasing overall clinical trial population.
Expanding Clinical Trials
Cancer Research Ideas - Expanding Clinical Trials (Archived)
Cancer clinical trials continue to be the gold standard by which new preventive, treatment, supportive care, and other interventions are tested and compared with existing interventions. New clinical trial designs are emerging with the recognition that a single cancer type may consist of many different molecular subtypes and that a given molecular alteration may drive many different types of cancer. At the same time, it is important that more patients have the opportunity to enroll in trials, to ensure that the results of trials are as broadly applicable as possible and that answers are obtained as quickly as possible.
The submission period for Expanding Clinical Trial ideas ended on July 1. However, we encourage you to sign up for regular e-mail updates about the National Cancer Moonshot Initiative at the Cancer Moonshot Milestones web page.
Shorten contracting by use of "umbrella" or "just in time" model. More patients accessed with less cost. Sites not added that may never accrue a patient.
Involve returning veterans: improving two areas at once -- training and employment for returning veterans and expanding trial participation.
Scientifically promising, affordable cancer treatment ideas may not reach patients because of a gap in our for-profit drug development model. A new NIH/NCI program should bridge this gap by facilitating and funding clinical trials of such agents.
The distribution of clinical trial "slots" to different participating institutions is a variable process. This could be standardized and made more efficient to fill trials more quickly and offer more opportunities to patients.
Prospective Trial of Library Access to Research Articles for Patient +/- Caregiver During Hospitalization or Chemotherapy Infusions
Conducting clinical trials is complex even for experienced institutions. Need more well-trained staff to execute clinical trials at more sites and speed up logistical process. Standardized protocols, forms, resource toolkits will also be valuable.
A natural compound blend shown to have dramatic anti-cancer activity as well as complement traditional cancer methods. Current self funded preclinical trial show apoptosis against glioblastoma, lung, prostate, and melanoma cancer cell line
My idea/comment is simple. FDA has to speed up the process for approving new drugs and treatments, especially for drugs used for late stages cancer. Those patients have little to lose,so no need to waste years testing drugs safety.
For 100% trial participation, each patient's cancer genomic data are computer analyzed to produce personalized maps of protein network abnormalities. Treatment arm assignment by digital drug screening. ddPCR to quantify response and adapt treatment.
There are local investigators and their staff already involved in conducting NCI clinical trial who have remarkable recruitment success. Whatever motivates them needs to be expanded to the general research community.
Need to enhance cancer patient enrollments!
Fund Nisin development, a naturally occurring product (from fermented sauerkraut) that has been tested by the University of Michigan and shrinks Squamous cell cancer by 70%. (NIH publication http://www.ncbi.nlm.nih.gov/pubmed/26132406)
Many new drugs (especially immunologics) are available only to stage 4 patients. Allowing stage 2 and 3 patients to participate in clinical trials of these new medications may prevent overt metastatic disease in stage 2 and 3 patients.
Let's suppose that chemo-drug is set in capsule of f.e. nano-tubes which are binding to cancer cells. In case such capsule is unstable in magnetic field we could deliver high dose chemo to ROI (region of interest).